Erythropoietin Reduces Post-PCI Arrhythmias in Patients with ST-elevation Myocardial Infarction

Journal of Cardiovascular Pharmacology

Volumn 65, Issue 6, 2015, Pages 555-561

  Gholamzadeh, Ali ^a   Amini, Sara ^a   Mohammadpour, Amir H ^b   Vahabzadeh, Maryam ^b   Fazelifar, Amir F ^c   Fazlinezhad, Afsoon ^a   Dehghani, Mashalla ^a   Moohebati, Mohsen ^a   Dastani, Mostafa ^a   Malaekeh Nikouie, Bizhan ^a   Falsoleiman, Homa ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

arrhythmia; erythropoietin; myocardial infarction

Indexed keywords

CREATINE KINASE MB; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOLOGIST; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE COUNT; FEMALE; HEART ARRHYTHMIA; HEMATOCRIT; HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE COUNT; ADVERSE EFFECTS; ARRHYTHMIAS, CARDIAC; BLOOD; COMPLICATION; DRUG EFFECTS; ELECTROCARDIOGRAPHY; IRAN; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PILOT STUDY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; BIOMARKERS; CREATINE KINASE, MB FORM; ELECTROCARDIOGRAPHY; ERYTHROPOIETIN; FEMALE; HEMODYNAMICS; HUMANS; IRAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84931563742     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000223     Document Type: Article

References (35)

1. Yesil M. Management of arrhythmias during transportation in patients with acute myocardial infarction. Anadolu Kardiyol Derg. 2007;7(suppl 1):85-87.
2. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for practice guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e385-e484.
3. Gillis DB, Hamilton DR. Estimating outcomes of astronauts with myocardial infarction in exploration class space missions. Aviat Space Environ Med. 2012;83:79-91.
4. Holler CP, Wichmann S, Nielsen SL, Moller AM. Large discrepancy between prehospital visitation to mobile emergency care unit and discharge diagnosis. Dan Med J. 2012;59:A4415.
5. Feltes TF, Bacha E, Beekman RH III, et al. Indications for cardiac catheterization and intervention in pediatric cardiac disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2607-2652.
6. Recommendations of a task force of the European Society of Cardiology and the European Resuscitation Council on the pre-hospital management of acute heart Attacks. Resuscitation. 1998;38:73-98.
7. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther. 2005;19:33-40.
8. Burger DE, Xiang FL, Hammoud L, et al. Erythropoietin protects the heart from ventricular arrhythmia during ischemia and reperfusion via neuronal nitric-oxide synthase. J Pharmacol Exp Ther. 2009;329:900-907.
9. Burger D, Xenocostas A, Feng QP. Molecular basis of cardioprotection by erythropoietin. Curr Mol Pharmacol. 2009;2:56-69.
10. Lipsic E, Schoemaker RG, van der Meer P, et al. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol. 2006;48:2161-2167.
11. Lipsic E, van der Meer P, Henning RH, et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol. 2004;44:473-479.
12. Westenbrink BD, Lipsic E, van der Meer P, et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J. 2007;28:2018-2027.
13. Lipsic E, van der Meer P, Voors AA, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther. 2006;20:135-141.
14. Nakamura R, Takahashi A, Yamada T, et al. Erythropoietin in patients with acute coronary syndrome and its cardioprotective action after percutaneous coronary intervention. Circ J. 2009;73:1920-1926.
15. Voors AA, Belonje AM, Zijlstra F, et al. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J. 2010;31:2593-2600.
16. Belonje AM, Voors AA, van Gilst WH, et al. Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III). Am Heart J. 2008;155:817-822.
17. Woo JS, Cho JM, Kim SJ, et al. Combined assessments of biochemical markers and ST-segment resolution provide additional prognostic information for patients with ST-segment elevation myocardial infarction. Korean Circ J. 2011;41:372-378.
18. Schroder R. Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation. 2004;110:e506-e510.
19. th ed. Philadelphia: Elsevier Saunders; 2011:2136.
20. Mehta RH, Starr AZ, Lopes RD, et al APEX AMI Investigators. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA. 2009;301:1779-1789.
21. Li J, Xu H, Gao Q, Wen Y. Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: a systematic review. Eur J Clin Pharmacol. 2012;68:469-477.
22. Wen Y, Xu J, Ma X, Gao Q. High-dose erythropoietin in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. 2013;13:435-442.
23. Winkler C, Funk M, Schindler DM, et al. Arrhythmias in patients with acute coronary syndrome in the first 24 hours of hospitalization. Heart Lung. 2013;42:422-427.
24. van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol. 2005;46:125-133.
25. Talan MI, Ahmet I, Lakatta EG. Did clinical trials in which erythropoietin failed to reduce acute myocardial infarct size miss a narrow therapeutic window? PLoS One. 2012;7:e34819.
26. Hamed S, Barshack I, Luboshits G, et al. Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J. 2006;27:1876-1883.
27. Ferrario M, Arbustini E, Massa M, et al. High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled study. Int J Cardiol. 2011;147:124-131.
28. Melloni C, Rao SV, Povsic TJ, et al. Design and rationale of the reduction of infarct Expansion and ventricular remodeling with erythropoietin after large myocardial infarction (REVEAL) trial. Am Heart J. 2010;160:795-803 e2.
29. Liem A, van de Woestijne AP, Bruijns E, et al. Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study. Int J Cardiol. 2009;131:285-287.
30. Radhakrishnan J, Upadhyaya MP, Ng M, et al. Erythropoietin facilitates resuscitation from ventricular fibrillation by signaling protection of mitochondrial bioenergetic function in rats. Am J Transl Res. 2013;5:316-326.
31. Singbartl G. Adverse events of erythropoietin in long-term and in acute/short-term treatment. Clin Investig. 1994;72:S36-S43.
32. Heinisch BB, Vcelar B, Kapiotis S, et al. The effect of erythropoietin on platelet and endothelial activation markers: a prospective trial in healthy volunteers. Platelets. 2012;23:352-358.
33. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood. 2000;95:2983-2989.
34. Ferrario M, Massa M, Rosti V, et al. Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction. Eur Heart J. 2007;28:1805-1813.
35. Ott I, Schulz S, Mehilli J, et al. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv. 2010;3:408-413.